Just 11 years after Emmanuelle Charpentier and Jennifer Doudna’s seminal CRISPR discovery, Casgevy marks the first approved gene-editing therapy, a major milestone for the field. This breakthrough signals the beginning of a revolution in treating genetic diseases, with a rapidly growing pipeline of precision genome-editing techniques emerging.

The 5th Genome Editing Therapeutics Summit (formerly the CRISPR 2.0 Sumit) is the leading industry event dedicated to advancing gene-editing technologies in therapy. Attendees can expect data-rich presentations, expert panels, and interactive sessions covering both established and emerging technologies. The summit will explore key topics such as novel nucleases, base and prime editing, multiplex editing, and precision tools enabling small and large genome modifications. Additionally, it will highlight epigenome editing, recombinase and transposon-based technologies, and innovative delivery vehicles.

Over three days, industry and academic leaders will present the latest research on cutting-edge therapies, discussing the safety, precision, and regulatory compliance necessary for successful development. This summit is the only event prioritizing drug development first, with a strong focus on creating robust safety profiles, detecting off-target effects, and facilitating investigational new drug (IND) filings.

Participants will gain actionable insights to improve the precision and safety of their technologies, enhancing their ability to perform targeted edits and streamline the path to the clinic for lead programs.

Join us and be part of the gene-editing revolution shaping the future of therapeutic development!